Skip to main content

Advertisement

SpringerLink
Log in

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).

Methods

One hundred and thirteen consecutive patients with previously untreated aggressive NHL (diffuse large B-cell lymphoma, 96; peripheral T-cell lymphoma, 17) prospectively participated in this study between 1995 and 2001. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.

Results

A high serum sIL-2R level (2,000 U/ml and over) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5-year, 24%) than those with low sIL-2R (under 2,000 U/ml) (74%) (P<0.01). Multivariate analysis employing sIL-2R levels and conventional prognostic factors demonstrated that high sIL-2R, presence of B-symptoms, and advanced age (60 years and older) were significantly unfavorable variables for overall survival. In addition, we attempted to use sIL-2R in combination with the International Prognostic Index (IPI). The patients in the high (H) risk group and those with high sIL-2R in the low-intermediate (LI)/high-intermediate (HI) risk group had significantly lower survival rates than the patients in the low (L) risk group and those with low sIL-2R in the LI/HI risk group (P<0.001).

Conclusion

The results suggest that a high serum sIL-2R level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a,b. a
Fig. 2a,b. a
Fig. 3a,b.

Similar content being viewed by others

References

  • Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ (2000) Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 96:1921–1925

    CAS  PubMed  Google Scholar 

  • Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511

    Article  CAS  PubMed  Google Scholar 

  • Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861

    CAS  PubMed  Google Scholar 

  • Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Kippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253

    CAS  PubMed  Google Scholar 

  • Cox DR (1972) Regression models and life-tables (with discussions). J R Stat Soc (Series B) 34:187–220

    Google Scholar 

  • Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F for the Group d’Etude des Lymphomes de I’Adulte (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. J Clin Oncol 15:1131–1137

    CAS  PubMed  Google Scholar 

  • Hara T, Tsurumi H, Takemura M, Goto H, Yamada T, Sawada M, Takahashi T, Moriwaki H (2000) Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin’s lymphoma. Am J Hematol 64:257–261

    Article  CAS  PubMed  Google Scholar 

  • Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutation of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534

    Article  CAS  PubMed  Google Scholar 

  • The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994

    Article  PubMed  Google Scholar 

  • Jaffe ES, Harris NL, Stein H, Vardiman JW, eds (2001) World health organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, 109–236

  • Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Google Scholar 

  • Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin’s lymphoma in the elderly. Am J Clin Oncol 13 [Suppl 1]:S15-S19

  • Kono N, Kanda Y, Yamamoto R, Chizuka A, Suguro M, Hamaki T, Arai C, Matsuyama T, Takezako N, Miwa A, Togawa A (2000) Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin’s lymphoma: a single center study in Japan. Leuk Lymphoma 37:151–156

    CAS  PubMed  Google Scholar 

  • Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261–268

    CAS  PubMed  Google Scholar 

  • Nicolaides C, Dimou S, Pavlidis N (1998) Prognostic factors in aggressive non-Hodgkin’s lymphomas. Oncologist 3:189–197

    PubMed  Google Scholar 

  • Niitsu N, Okabe-Kado J, Kasukabe T, Yamamoto-Yamaguchi Y, Umeda M, Honma Y (1999) Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin’s lymphoma. Blood 94:3541–3550

    CAS  PubMed  Google Scholar 

  • Niitsu N, Iijima K, Chizuka A (2001) A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Eur J Haematol 66:24–30

    Article  CAS  PubMed  Google Scholar 

  • The non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute-sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135

    Google Scholar 

  • Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndrome: a relationship with disease subtype and clinical outcome. Brit J Haematol 93:45–52

    Article  CAS  Google Scholar 

  • Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186–194

    CAS  PubMed  Google Scholar 

  • Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135:3172–3177

    CAS  PubMed  Google Scholar 

  • Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 113:619–627

    CAS  PubMed  Google Scholar 

  • Salven P, Teerenhovi L, Joensuu H (1999) A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin’s lymphoma. Blood 94:3334–3339

    CAS  PubMed  Google Scholar 

  • Sasaki K, Niitsu N (2000) Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 65:195–202

    Article  CAS  PubMed  Google Scholar 

  • Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361

    Article  CAS  PubMed  Google Scholar 

  • Semenzato G, Foa R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M, Pizzolo G (1987) High serum levels of soluble interleukin-2 receptor in patients with B chronic lymphocytic leukemia. Blood 70:396–400

    CAS  PubMed  Google Scholar 

  • Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphoma: Report of the July. J Clin Oncol 17:423–429

    CAS  PubMed  Google Scholar 

  • Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin’s lymphoma. Brit J Haematol 88:770–777

    CAS  Google Scholar 

  • Takagi T, Oguro M (1987) (2”-R)-4’-o-Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151–154

    CAS  PubMed  Google Scholar 

  • Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or biweekly THP-COP regimens in the treatment of aggressive non-Hodgkin’s lymphoma: a comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113

    Article  CAS  PubMed  Google Scholar 

  • Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G (1998) Soluble interleukin-2 receptors (sIL-2R) in Hodgkin’s disease: outcome and clinical implications. Brit J Cancer 77: 992–997

    CAS  PubMed  Google Scholar 

  • Wagner DK, Kiwanuka J, Edwards BK, Rubin LA, Nelson DL, Magrath IT (1987) Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. J Clin Oncol 5:1262–1274

    CAS  PubMed  Google Scholar 

  • Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, Matsuoka M, Hattori T, Takatsuki K, Purtilo DT (1988) Soluble interleukin-2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71:1021–1026

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, 501-1194, Gifu, Japan

    Hideko Goto, Hideko Goto, Hisashi Tsurumi, Yoriko Ino-Shimomura, Senji Kasahara, Michio Sawada, Toshiki Yamada, Takeshi Hara, Kenji Fukuno, Naoe Goto, Naoe Goto, Masataka Okuno & Hisataka Moriwaki

  2. Department of Clinical Laboratory, Gifu University Graduate School of Medicine, Gifu, Japan

    Masao Takemura & Mitsuru Seishima

  3. Department of Cellular Pathology, Gifu University Graduate School of Medicine, Gifu, Japan

    Tsuyoshi Takami

Authors
  1. Hideko Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hisashi Tsurumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masao Takemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoriko Ino-Shimomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Senji Kasahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michio Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Toshiki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takeshi Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kenji Fukuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Naoe Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masataka Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tsuyoshi Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mitsuru Seishima
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Hisataka Moriwaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisataka Moriwaki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goto, H., Tsurumi, H., Takemura, M. et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. J Cancer Res Clin Oncol 131, 73–79 (2005). https://doi.org/10.1007/s00432-004-0600-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-004-0600-9

Keywords

Search

Navigation